| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 192.3 | 180.2 | 153.9 |
| Other income | 8.9 | 2.8 | 13.2 |
| Total income | 201.3 | 183.0 | 167.2 |
| Profit before exceptional items & tax | 47.6 | 39.5 | 40.6 |
| Profit before tax | 47.6 | 39.5 | 40.6 |
| Net profit | 36.6 | 30.4 | 30.1 |
| Operating margin | 23.6% | 21.6% | 24.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +21.60% |
|---|---|
| Net profit, quarter on quarter | +20.40% |
| Revenue, year on year | +25.00% |
| Operating profit, year on year | +41.20% |
| Operating profit, quarter on quarter | +5.40% |
BSE results filing, NSE: SENORES. Figures extracted from the filing.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,294.80
- Market cap
- ₹5,963 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 47.2×Sector 46.1×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Senores Pharmaceuticals Results Update
Senores reported Q2 FY27 revenue of ₹192 cr and EBITDA of ₹58 cr, both record highs. PAT grew 22% Y-o-Y to ₹37 cr with positive FY27 outlook.
Senores Pharmaceuticals Capacity Expansion: ₹43 Cr Investment
Senores Pharmaceuticals disclosed capacity expansion at three subsidiaries with total estimated cost of ₹43 Crore. Expansions adding ~1.5 Bn units/annum are expected by March 2027.
- Value
- ₹43.00 Cr
- Execution
- By end of March 2027
- manufacturing capacity addition (per annum)
- 1502.7 Mn units
Senores Pharmaceuticals Board Meeting Date
Senores Pharmaceuticals has scheduled a board meeting for October 29, 2026, to approve its unaudited financial results for the quarter and half-year ended September 30, 2026.
Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals Limited has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of its Managing Director and Whole Time Director. The e-voting period concludes on November 17, 2026.
Senores Pharmaceuticals Management Change
Senores Pharmaceuticals re-appointed Swapnil Shah as MD and Chetan Shah as WTD for three-year terms. Both appointments are subject to shareholder approval via postal ballot.